Driving their expertise in genomics-based health and disease testing, Genetic Technologies (ASX: GTG) has partnered CancerIQ, a widely used platform that assists healthcare providers identify high-risk patients and prioritise preventive cancer screenings. CancerIQ has become a resource for healthcare institutions and clinics by simplifying the identification of individuals at risk for hereditary cancers. By embedding
Read More
Ever thought about how your chin resembles your father? Or your eye colour resembles your great grandmother – it’s all in the genes right! Genetics and DNA lie at the heart of biological sciences. Genetic Technologies (ASX: GTG) is initiating a strategic transformation to enhance prospects and financial stability. The plan involves operational restructuring to
Read More
Molecular diagnostics company Genetic Technologies (ASX: GTG) is piloting its risk assessment test geneType in breast screening centres across the US. The Company is establishing a clinical implementation study with breast imaging centres in New York, Miami and Houston. In the US, screening is currently between the ages of 40 and 74. So, the current
Read More
According to the US Food and Drug Administration (FDA), Precision Medicine, or “personalised medicine”, is a new way of tailoring disease care by considering people’s unique genes, environments, and lifestyles. The goal is to give the right treatments at the right time.
Read More
In 2022, over 24k Aussie males were diagnosed with prostate cancer. One of the most commonly diagnosed cancers, it was also the third most common cause of cancer death in Australia in 2020. Its high prevalence and the cocktail of concerns that come with it have prompted the need for better diagnosis mechanisms than the
Read More
